Discovery Lecture Series

(iStock image)

Blood formation and disorders expert Stuart Orkin to present Discovery Lecture March 27

Orkin’s research led to a gene therapy for sickle cell disease and beta-thalassemia; it is the first Food and Drug Administration-approved CRISPR-based gene therapy.

From left, 2024 Vanderbilt Prize winner Sarah Tishkoff and Vanderbilt Prize Student Scholar Kimberlyn Ellis. (photo by Susan Urmy)

Evolution, genomics and disease: a very special Discovery Lecture

Sarah Tishkoff described her groundbreaking research during a talk titled “African Evolutionary Genomics: Reconstructing Human Evolution and the Genetic Basis of Complex Adaptive Traits.”

Sarah Tishkoff, PhD

Vanderbilt Prize winner to discuss ‘evolutionary genomics’ on March 6

Tishkoff’s groundbreaking research at the University of Pennsylvania has broad implications for understanding and treating human disease.

From left are Alvin Powers, MD, Daniel Drucker, MD, and Steven Eskind, MD, associate professor of Surgery, son of Annette and Irwin Eskind. (photo by Donn Jones)

Leading GLP-1 expert shares insights on groundbreaking drugs for glucose control, weight loss

Drucker and his team study the molecular biology and physiology of the GLP-1 and GLP-2 molecules that regulate glucose metabolism, insulin secretion and energy balance.

GLP-1 medicines are focus of Discovery Lecture on Nov. 21

Daniel Drucker, MD, a pioneering scientist whose research contributed to the development of the blockbuster GLP-1 medicines used to treat diabetes and obesity, was listed by TIME magazine as one of the 100 Most Influential People of 2024.

From left, Bradley Malin, PhD, Microsoft chief scientific officer Eric Horvitz, MD, PhD, and Peter Embí, MD, MS, addressed last week’s ADVANCE symposium on health care AI. (photo by Donn Jones)

Patient voices critical to success of artificial intelligence in health care

Sponsored by the Department of Biomedical Informatics, the symposium showcased the work of the department’s center for AI Discovery and Vigilance to Accelerate Innovation and Clinical Excellence.

1 2 3 21